Previous 10 | Next 10 |
Introduction Antares Pharmaceuticals ( ATRS ) is a developer of intramuscular and subcutaneous injection devices including the VIBEX and VIBEXQuickShot pressure-assisted delivery systems. The company possesses several promising candidates in its pipeline; performed an impressive XYOSTED laun...
EWING, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares” or “the Company”) today announced that it has entered into an amendment to its existing loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), (“He...
EWING, N.J., June 11, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James 2019 Life Sciences and MedTech Conference on Tuesday, June 18, 2019 at 10:20 a.m. Eastern Time. ...
As the chart below illustrates, Antares Pharma ( ATRS ) stock has been down and under pressure since the FDA approval of Clarus Therapeutics' TRT drug Jatenzo on March 28, which gives an indication of lower investor sentiment and expectations. (Courtesy StockCharts.com) After reaching an i...
EWING, N.J., May 30, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019 at 11:00 a.m. Eastern Time. A live webcast of ...
EWING, N.J., May 16, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Fred M. Powell, Executive Vice President and Chief Financial Officer, will present at the B. Riley FBR Institutional Investor Conference on Thursday May 23, 2019 at 1:30 pm Pacific Dayligh...
The following slide deck was published by Antares Pharma, Inc. in conjunction with their 2019 Q1 earnings Read more ...
Antares Pharma, Inc. (ATRS) Q1 2019 Earnings Conference Call May 2, 2019 08:30 a.m. ET Company Representatives Bob Apple - President, Chief Executive Officer Fred Powell - Executive Vice President, Chief Financial Officer Jack Howarth - Vice President of Corporate Affairs Conf...
Antares Pharma (NASDAQ: ATRS ): Q1 GAAP EPS of -$0.03 beats by $0.01 . More news on: Antares Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
EWING, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”) today reported operating and financial results for the first quarter ended March 31, 2019. The Company reported revenue of $23.3 million and a net loss per share of $0.03 fo...
News, Short Squeeze, Breakout and More Instantly...
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced that the waiting period unde...
Antares Pharma Inc shares ( NASDAQ: ATRS ) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The deal translates to $5.60 per share for Antares Pharma shareholders that...